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Abstract: The review focuses on the application of supercritical fluids as antisolvents in the 
pharmaceutical field and demonstrates the supercritical antisolvent method in the use of drug 
encapsulation. The main factors for choosing the solvent and biodegradable polymer to pro-
duce fine particles to ensure effective drug delivery are emphasized and the effect of polymer 
structure on drug encapsulation is illustrated. The review also demonstrates the drug release 
mechanism and polymeric controlled release system, and discusses the effects of the various 
conditions in the process, such as pressure, temperature, concentration, chemical compositions 
(organic solvents, drug, and biodegradable polymer), nozzle geometry, CO2 flow rate, and the 
liquid phase flow rate on particle size and its distribution.
Keywords: supercritical antisolvent method, drug encapsulation, particle size, drug release 
mechanisms, drug delivery
Introduction
Drug delivery includes important situations such as the slow release of soluble drugs in 
water, the rapid release of low-solubility drugs, drug delivery to specific sites, and the 
delivery of more than one agent with the same formulation and system based on soluble 
or degradable carriers that are easily eliminated. The ideal drug delivery method should 
be safe, inert, and comfortable for the patients. It should also be biocompatible, and 
easily administered or removable, with high drug loading and easy fabrication/sterilizing 
ability. Using biodegradable polymers for drug encapsulation is one of the best ways 
to achieve this ideal method. The biodegradable polymer first combines with the drug 
and then coats it; therefore, if the drug is released from the encapsulated material in a 
predesigned manner, controlled drug delivery will occur. Drug release can be constant or 
cyclic over a long-term period, or it may be activated by the environment or other external 
events. Therefore, drug delivery control provides more effective therapies, and avoids the 
potentials above or below the dosing range. Besides, the coating polymer protects the 
susceptible active substance from degradation. However, there are some limitations, such 
as the possible nonbiocompatibility or toxicity of the polymers, an unwanted byproduct of 
degradation, and higher costs.1–3 Biodegradable polymer drug nanoencapsulation reduces 
drug side effects, and increases the bioavailability and sustained release. Bioavailability 
of pharmaceutical compounds depends on their absorption by the gastrointestinal tracts 
which is affected by both the dissolution rate and membrane permeation rate. During 
the supercritical antisolvent (SAS) process the surface area will be increased, which 
leads to improvement of bioavailability. It is also crucial in controlling the particle size 
and its distribution for efficient drug delivery. Obviously, the smaller particles with International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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narrower particle size distribution result in better flexibility 
of administration. Further, increasing the bioavailability 
decreases the required drug dosage and raises the control over 
a sustained period.4–9 Smaller-sized particles can accelerate 
toward the target organs, and distribute drug evenly throughout 
the body. Additionally, the drug dosage can be controlled by 
biodegradable polymers, so that the polymers can actually 
control the periodic time of release. The particle size must be 
between 1 and 5 µm for inhalation delivery, between 0.1 and 
0.3 µm for intravenous delivery, and between 0.1 and 100 µm for 
oral delivery.1,4,10–12 Therefore, drug nanoencapsulation becomes 
crucial in successful drug delivery. The usage of supercritical 
fluid for the purpose of drug nanoencapsulation is a clean and 
effective method compared with other techniques.4,5,7–9
Supercritical fluid properties
A supercritical fluid is a solvent whose temperature and pres-
sure are greater than its critical temperature and pressure, 
while it remains as a single phase, as shown in Figure 1.13 CO2 
supercritical fluid is the best choice, from among the others 
available for pharmaceutical processes, as it is affordable, 
nontoxic, and inflammable. Further, it has high volatility, 
mild critical temperature (304°K), low critical pressure 
(7.38 MPa), low cohesive energy density, low polarizability 
per unit volume, and poor solubility for many polymers and 
drugs,8,10,13,15,16 and it has low viscosity like a gas, although 
its density is similar to that of a liquid. Around the critical 
point, its properties such as density, viscosity, solvency, and 
diffusivity can be manipulated by adjusting the pressure and 
temperature.13,14,17
Due to its low viscosity, it reveals a high mass transfer 
ratio during the SAS process. Besides, it has high   diffusivity, 
typically 10-3 cm2/second in organic solvents, which   promotes 
rapid mixing with the solvent in the nucleation step, for 
approximately 10-4 to 10-5 seconds. Further, the solvating 
power can be controlled by adjusting both pressure and 
temperature, so that it produces dry particles by removing 
the organic solvents in a continuous single step of the SAS 
process.6,14,17,18 The interaction between the solute and the 
solvent in supercritical fluids is explained in a similar   manner 
to the three-density region solvation model.13,19 Another 
important advantage of the CO2 supercritical fluid (ScCO2) 
lies in its ability to provide a nondegrading and nonoxidiz-
ing environment for sensitive compounds. Also, its drying 
process prevents damage to the drug particles.14
The solubility of polymers in ScCO2 and conversely the 
solubility of ScCO2 in polymers are the two main aspects that 
need further study. CO2 is a nonpolar molecule possessing a 
small polarity due to its quadruple moment. Thus, nonpolar 
and light molecules with higher vapor pressure can be easily 
dissolved in the CO2 compared with heavy molecules, and 
polar molecules with lower vapor pressure. Most polymers 
and drug compounds have low solubility in ScCO2, whereas 
ScCO2 easily dissolves in most biodegradable polymers, and 
dramatically reduces the glass transition temperature and melt-
ing temperature of the polymers; thus, the viscosity of polymers 
will be reduced.5,15,17,19,20 Drug solubility in the ScCO2 depends 
on the vapor pressure of the drug, the interaction between the 
drug and CO2, and the density of the supercritical fluid.17,21
The antisolvent application
Bleich and coworkers firstly discovered the use of antisolvent 
techniques in encapsulation.15 In this technique, CO2 acts as 
an antisolvent and causes the precipitation of a solute from 
an organic solvent. The base of this technique is:
  i. The possibility of dissolving a large volume of a super-
critical fluid by an organic solvent.
 ii. The reciprocal miscibility of the supercritical fluid CO2 
and an organic solvent.
iii. The low affinity of the supercritical fluid for the solute.
CO2 is diffused in the solvent and evaporates in the gas phase. 
The droplets are expanded and stabilized by surface tension. 
The mass transfer between the supercritical fluid and liquid 
phase decreases the surface tension which is strong enough 
to control droplet shape. Diffusion phenomenon increases 
the volume of the solvent, reduces the density of the solvent, 
thus decreasing the solvating power of the solvent, and pre-
cipitates the solute.1,4,6,12,14,19,20,22–24 Different densities between 
the liquid phase and the supercritical fluid phase significantly 
affect the mass transfer. Besides, the high diffusivity of the 
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Figure 1 Triple point phase diagram for pure CO2.7,14
Note:   Adapted  with  permission  from:  Ginty  PJ,  whitaker  MJ,  Shakesheff  KM, 
Howdle SM. Drug delivery goes supercritical. Materials Today. 2005;8(8) Suppl 1: 
42–48. Copyright 2005 American Chemical Society; and: reprinted from International 
Journal of Pharmaceutics, vol 364, Are pharmaceutics really going supercritical?, pages 
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supercritical fluid is another factor that produces the high rate 
of mass transfer. The high pressure vapor–liquid equilibrium 
phase of the ternary system controls the precipitation of the 
solute in the SAS process.19
SAS
This process refers to the precipitation in a supercritical fluid 
due to particle formation. The supercritical antisolvent must 
be miscible with the solution solvent, and the solute must 
also be insoluble in the supercritical antisolvent. In the SAS 
process, the supercritical CO2 is pumped into a high-pressure 
vessel to a specific pressure. Then the solution, including the 
drug, biodegradable polymer, and organic solvent, is sprayed 
in the reactor via a suitable nozzle. The solvent diffuses 
rapidly from the solution droplets into the bulk supercritical 
fluid, precipitating the solute. Formed particles are col-
lected on a filter washed by supercritical fluid to remove the 
residual solvent.5,13,14,19,22,25,26 Therefore, the supercritical fluid 
dissolving into liquid droplets, together with the evaporation 
of the organic solvent in the supercritical fluid phase, provides 
a supersaturated solute in the liquid phase, which will be later 
precipitated. A schematic diagram of the apparatus for the 
SAS process is shown in Figure 2.
The advantages of this method are:
 i.  During this process a very fine dispersion of liquid phase 
occurs, so there is a very fine droplet and a high specific 
surface area for mass transfer.5,20,23,24,28,29
ii.  Freshly precipitated particles will remain in the system 
and the supercritical fluid and organic solvent drain from 
the system continuously.20,27,30,31
  iii.    High supersaturation is achieved and, therefore, 
small particle size is attained due to the rapid mix-
ing of the supercritical fluid and solution (liquid 
phase).5,17,24,25,31,32
   iv.    By controlling the operating condition, it is possible to 
produce narrower particles.25,32
   v.    By reducing the pressure or depressurizing, the 
supercritical fluid is more easily removed from the 
system.20,21,24,29,32–34
   vi.    The process can take place at near ambient temperatures, 
thus avoiding thermal degradation of the particles by 
choosing a suitable antisolvent.32,33
 vii.    Before recovering the solid, relatively high amounts of 
liquid solution can be processed.27
viii.    This process can prepare drug-encapsulated particles 
with high polymorphic purity, enhanced dissolution 
rate, and acceptable residual solvent.35
   ix.    This method is adaptable for continuous operations, and 
this property is very important for the large-scale mass 
production of nanoencapsulated drug particles.24
Some experiments are summarized in Table 1.
Despite all these advantages, there is a limitation to the 
success of this method for drugs and biodegradable polymers 
that occur as solids.20 The major disadvantage of this method 
is the long washing period prior to the agglomeration and 
aggregation of particles. This problem can be minimized 
by intensively mixing the supercritical antisolvent and the 
solution, which increases the mass transfer and thus pro-
duces smaller particle size. One of the methods to achieve 
intensive mixing is by using ultrasonic nozzles. During this 
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Table 1 Summary of literature reviews
Compound Solvent Polymer Particle size Ref
Bupivacaine HCl DCM/acetonitrile/potassium 
phosphate and sodium azide
PLGA/PLLA 4–10 µm 31
Diuron DCM PLLA Needle-like crystals mean length 500 µm 27
Amoxicillin NMP – 0.3–1.2 µm 26
europium acetate DMSO – 0.2–10 µm 36
Cilostazol DCM   Irregular crystals 0.9–4.52 µm 37
Gadolinium acetate DMSO – 0.2–10 µm 36
Amoxicillin NMP – 0.25–1.2 µm 38
Fluconazole DCM, acetone and ethanol – Needle like crystals several hundred µm 39
Nalmefene hydrochloride ethanol – Above the MCP 200–300 nm, near and below  
the MCP 0.5–2 µm
40
Zinc acetate – – 50 nm 41
Salbutamol sulphate DMSO – Length 1–3 mm and diameters 0.2–0.35 mm 43
Tetracycline NMP – Needle-like particles irregular amorphous particles  
0.6–0.8 µm 150 nm
44
Rifampicin DCM PLLA ,5 µm 11
Methylprednisolone acetate Tetrahydrofuran – 4–10 µm 45
Amoxicillin DMSO – Amorphous spherical particles 0.2–1.6 µm 34
Chlorpropamide etAc – Platy crystals several tenths µm 46
Chlorpropamide Acetone – Columnar habit crystals several tenths µm 46
Sulfathiazole Acetone – Prismatic crystals .750 µm 46
Sulfathiazole MeOH – Needle-like, tabular crystal habit .750 µm 46
Ampicillin NMP – Aggregate and separated amorphous spherical  
particles 0.26 µm
47
Ampicillin etOH – Aggregate and separated amorphous spherical  
particles 1.26 µm
47
Rifampicin DMSO – Amorphous particles, coalescent nanometric spherical  
separated icrometric mean 0.4–1 µm 2.5–5 µm
36
Arbutine etOH – 2.4–4.7 µm 48
L-PLA DCM – Agglomerate particle ,4 µm 28
Oxeglitizar etOH+ CHCl3, etOH 
hydrocortisone
PeG/PvP Needle crystals, polymorphic form A size .50 µm 35
Oxeglitizar THF, DCM PeG/PvP Needle-like crystals, polymorphic form A,  
traces form B size .50 µm
35
Oxeglitizar etOH/THF(50:50), etOH PeG/PvP Needle-like crystals, polymorphic form A and  
form B size .50 µm
35
Cefonicid DMSO – Spherical submicroparticles and empty shells from  
0.2 µm to .50 µm
29
Sulfamethizole Acetone – Thin platy ,56 µm/tabular ,220 µm 49
Silica – eudragit RL100 50 µm 50
– DMSO Dextran Spherical particles mean 5–100 µm 38
– DMSO HPMA Spherical particles 100–200 nm 38
– DMSO Inulin Irregular particles 5–50 mm 38
– DCM L-PLA Spherical particles mean 1–4 mm 38
Cyclotrimethylenetrinitramin DMSO – Granular mean size 12.8 µm 51
RDX ACN – Granular mean size 6.6 µm 51
RDX Acetone – Rob shaped granular 17.7 µm 51
RDX DMF – Granular mean size 5.1 µm 51
Cyclotrimethylenetrinitramin NMP – Irregular mean size 11.4 µm 51
Cefoperazone DMSO – Submicro particles, micropetric particles,  
large crystals 0.25–0.5 µm
52
Cefuroxime DMSO – Submicro particles, wrinkled microparticles, balloons 
0.1–0.9 µm, 1–3 µm, 5–20 µm
52
Trypsin/lysozyme DMSO – Irregular coalescing particles 1–5 µm 53
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process, 10 to 100 kHz ultrasonic waves produce ultrasonic 
vibrations which enhance the mass transfer rate between the 
supercritical fluid and solution; therefore, smaller droplets 
will be formed, which results in smaller particles.1,13,23,58 Using 
additional solvents in the SAS process causes a broad range 
of solutes to dissolve in the organic solvents. Therefore, the 
presence of residual toxic solvents in the final product is the 
only disadvantage of this process.7,24
Drug
It is possible to encapsulate pharmaceutical compounds using 
the SAS process.36 The structure of drugs and their properties 
are important factors in produced particle size in the SAS 
process.59 Drug loading efficiency has been observed to be 
strongly related to the nature of the drug. For example, lipophilic 
drugs or CO2-soluble drugs are difficult to load.24 The process 
parameters have less effect on the drug loading because of 
the solute particles that are precipitated from the solvent.23,60 
By decreasing the ratio of the polymer to drug, supercritical 
fluid is saturated with the drug and the drug loading efficiency 
will be enhanced.11 Drug loading in drug encapsulation is 
explained by the ratio of mass fraction of a nanoencapsulated 
drug to the total mass of the sample, according to the following 
equation:4,9,11,61–63
 
Drug loading
Massof nano encapsulated drug
Totalm assof parti
(%) =
-
c cles
× 100% (1)
and,
Theefficiencyofd rugloading
Actualdrugloading
Theoretical
(%) =
d drugloading
×100%  
(2)
The particle size of the microparticles is determined by 
the volume mean diameter. The microparticles’ polydispersity 
is expressed by the span value:11
 
Span
DD
D
=
- 90 10
50
%%
%
  (3)
where D90%, D10%, and D50% are the equivalent   volume 
diameters at 90%, 10%, and 50% of the cumulative 
volume.11
Solvent
Most polymers have a limited solubility in the supercritical 
fluid, although they have high solubility in the organic 
solvents. Thus, a critical factor in the SAS process is the selec-
tion of the correct combination of a suitable organic solvent 
and a supercritical fluid as antisolvent.24 Further, selecting a 
suitable solvent for drug nanoencapsulation is very important, 
as the molecules could be polar and multifunctional with a 
tendency toward hydrogen bonding. This will create a special 
interaction between the solvent and solute.21
The pharmaceutical agents must also be soluble in a suit-
able organic solvent that is miscible with the supercritical 
fluid. Thus, there is a limitation in the choice of compounds 
and solvents, which usually causes failure in the SAS 
  process. In reality, there is no problem for the solubility of 
hydrophobic compounds of low molecular weight in the 
organic solvent; however, complex hydrophilic compounds 
are mostly insoluble in most of organic solvents. Therefore, 
supercritical fluid miscible organic solvents such as dimethyl 
sulfoxide (DMSO) are suitable to dissolve the biological 
molecules. When these compounds are dissolved in such 
Table 1 (Continued)
Compound Solvent Polymer Particle size Ref
Theophylline etOH/DCM – lamellar crystals and rosette crystals  
L/d = 5–300 µm/1–100 µm
54
– DCM + DMSO ethylcellulose/
methylcellulose
Spherical coalescing particles 5 µm 55
– DCM L-PLA Spherical particles or fibers 1–5 µm 27
– DCM L-PLA Fibers and/or microspheres mean 1–3 µm 56
– DCM L-PLA Coalescing particles 3–15 µm 28
Nimesulide CHCl3, DCM – Needle and thin rod-shaped crystals Form I 57
Nimesulide Acetone – Needle and thin rod-shaped crystals, 
meta-stable Form II
57
Rifampicin DCM L-PLA Spherical particle ,5 µm 11
Abbreviations: CHCl3, chloroform; DCM, di-chloromethane (methylene chloride); PLGA, polylactic-co-glycolic acid; etAc, ethyl acetate; etOH, ethanol; MeOH, methanol; 
PLLA,  L  poly  lactic  acid;  NMP,  N-methyl-2-pyrrolidone;  oxeglitazar,  (2e,  4e)-5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic 
acid; DMSO, dimethyl sulfoxide; MCP, melting critical point; THF, tetrahydrofuran; PeG, polyethylene glycol; PvP, polyvinylpyrrolidone; HPMA, N-(2-hydroxypropyl) 
methacrylamide; L-PLA, L-polylactic acid; ACN, acetonitrile; DMF, dimethylformamide.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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solvents, the molecules irreversibly change their structure 
and lose their functional activity and immunogenicity risk. To 
overcome this setback, a suitable cosolvent, such as ethanol, 
can be used to enable the water to mix with the supercriti-
cal fluid CO2.15 The organic solvent should be reasonably 
soluble in the polymer and show high mutual solubility with 
the supercritical fluid under moderate operating pressure 
and temperature. The complete miscibility or high mutual 
solubility with CO2 in the near and supercritical region is 
observed by most organic solvents to dissolve a particular 
polymer.24 The volumetric expansion of the organic solvent 
in the precipitation process clearly plays an important role. 
This expansion results from an expanded dissolution of the 
supercritical fluid in the liquid phase.24,41 The volume expan-
sion can be calculated as follows:
 
V
VPTV
V
(%)
(,)
% =
-
×
0
0
100   (4)
where V(P,T) is the volume of the liquid phase (organic 
solvent) loaded with the supercritical fluid as antisolvent, 
at the operating pressure and temperature, and V0 is the 
volume of the pure liquid (pure organic solvent) at atmo-
spheric conditions.41,42 When the volume expansion is low, 
the precipitated particles from the liquid phase will form 
at the bottom of the vessel. Incomplete dissolution of the 
solvent liquid occurs in the supercritical fluid as antisolvent 
produces the liquid phase in the precipitator. When the vol-
ume expansion is intermediate, dried expansion droplets will 
be formed and an empty shell of solute will be produced. 
In a very large volume expansion, the precipitated particles 
are very small and the particle size distribution is narrow. 
The aim of encapsulation is to choose an organic solvent 
with high volume expansion.41 Sometimes, in spite of an 
asymptotic expansion of the liquid organic solvent obtained 
according to the pure solvent curve, a liquid phase can be 
observed at the bottom of the chamber. This failure is due to 
the presence of a solute that modifies the phase behavior of 
the solvent–antisolvent mixture. In this case, a film or large 
solute crystals will be produced in the precipitator instead 
of small particles.41
According to the drug and biodegradable polymer struc-
ture and operating conditions, selecting a suitable solvent is 
crucial to the SAS process. These two key points must be 
considered: At first, an organic solvent with high volatil-
ity which induces high volume of expansion and which 
can also be removed from the system easily needs to be 
selected. The solubility of the biodegradable polymer in the 
organic solvent needs to be higher than the solubility of the 
drug in the   solvent, because the drug first precipitates in the 
chamber, then it is coated by the biodegradable   polymer 
by precipitation, and finally drug encapsulation by the 
biodegradable polymer occurs.27 Therefore, the selection 
of suitable solvent is an important factor to produce fine 
particles in SAS process.
Biodegradable polymer
The selection of a suitable biodegradable polymer is another 
important factor in the nanoencapsulation of drug that attracts 
a lot of attention due to biodegradable polymer’s ability to 
be reabsorbed by the body.64 Compatibility between the drug 
and polymer is vitally significant. These nanoencapsulated 
particles decrease the side effects of the drug, and also extend 
the circulation time in the bloodstream and target the drugs to 
specific organs.65 Furthermore, biodegradable drug delivery 
mechanisms can be designed to deliver vaccines in a number 
of pulses from a single injection of microencapsulated drug.64 
The degree of polymer degradation can be increased by add-
ing more hydrophilic backbone or end groups. The higher 
number of the reactive hydrophilic groups in the backbone, 
the less the degree of crystallinity; and the higher porosity, 
the smaller the size of the device.62,66
Supercritical CO2 decreases the glass transition tem-
perature of biodegradable polymers, acting like a plasticizer. 
Therefore, these polymers with a low glass transition tem-
perature tend to form sticky and aggregated particles.30,67 
However, the presence of residual organic solvents in the 
product increases the plasticizing effects.15,68 However, the 
crystalline biodegradable polymers are better suited for drug 
delivery of some extremely potent drugs such as vaccines and 
drug-eluting medical devices. Their restrictions are because of 
their very long in vivo degradation time, slow releasing period, 
and application that is drawn out and infrequent, whereas most 
drugs require frequent delivery over a few weeks. Dose fre-
quency of the drugs is controlled by the stability of the drugs 
in the biodegradable polymeric system and their therapeutic 
potency. For faster drug delivery, amorphous polymers are 
used.15,35,64,68,69 The polymer chains of biodegradable polymers 
usually hydrolyze into biologically acceptable progressive 
smaller compounds, and degrade so that they can be removed 
easily from the body by metabolic pathways. Degradation 
phenomenon may occur through bulk hydrolysis and the 
polymers degrade uniformly throughout the matrix. Factors 
affecting the biodegradation of polymers are:2
 i.  Chemical composition of polymer.
ii.  Chemical structure of polymer.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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    iii.  Configuration structure.
    iv.  Morphology of polymer.
     v.  Molecular weight of polymer.
    vi.  Molecular weight distribution.
   vii.  Shape of polymer.
  viii.    Physicochemical factors such as ionic strength   
and pH.
    ix. Annealing.
     x.  Processing condition.
    xi.    Physical factors such as changes in shape and size, 
mechanical stress, changes in diffusion factor.
   xii. Adsorbed and absorbed compounds.
  xiii.  Mechanism of hydrolysis.
  xiv.  Repeating units distribution in multimers.
   xv.  Presence of compounds with low molecular weight.
  xvi.  Ionic groups present.
  xvii.  Unexpected units or chain defects present.
xviii.  Sterilization process.
  xix.  Site of implantation.
   xx.  Storage history.
Effects of process parameters  
on particle size
The characteristics of the particle produced in the SAS 
method for drug encapsulation are influenced by various 
parameters such as type of supercritical fluid and its proper-
ties, properties of the solute including the drug, biodegradable 
polymer, and organic solvent, and operating conditions such 
as temperature, pressure, concentration, nozzle geometry, 
feed flowrate, the rate of antisolvent, and the degree of 
mixing.13,22,70 Therefore, optimization of these parameters 
to produce the smaller mean particle size with narrower 
distribution becomes crucial.
effects of pressure and temperature
The density of supercritical fluid affects mass transfer 
between organic solvent and supercritical fluid during 
  precipitation. The density of supercritical fluid depends 
on the temperature and pressure parameters of the fluid, as 
shown in Figure 3.
Near the critical point, a small change in the pres-
sure causes considerable density changes, as shown in 
Figure 3.5,16,17,63
Hydrodynamic theory, such as Weber numbers, have 
been applied to the supercritical antisolvent process. Weber 
number is the proportion of the deforming external pressure 
and reforming surface tension forces, such as:
  NU D wA R ε ρσ =
2 /   (5)
where, ρA is the density of antisolvent, UR is the relative 
velocity, D is the initial droplet diameter, and σ is the inter-
face tension.
Increasing the ratio of deforming external pressure forces 
with respect to the reforming surface tension forces the drops 
to break up into smaller droplets. During the SAS process, 
the Weber number is very high compared with that in other 
techniques.12,28,40,56,63 The solubility of high-molecular-weight 
drugs in the supercritical fluid is related to the density. The 
solubility increases at higher densities and the effect of 
density on particle solubility is rapidly enhanced at higher 
densities. Increase in density enhances the molecular inter-
action, and, thus, the solubility.16,17,21 The effect of pressure 
on particle size produces various results according to these 
experiments. At higher pressure with higher density of 
supercritical fluid (antisolvent), the deforming pressure forces 
must be increased to break the droplets into smaller particles, 
according to the explanation given above.63 Moreover, par-
ticle nucleation and its growth are other important factors 
affecting particle size. Rapid mass transfer of antisolvent and 
solvent causes high supersaturations for the solute.56 High 
supersaturation results in rapid nucleation and growth of 
more than one particle per primary droplet.71 The solubility 
of supercritical CO2 will vary with pressure. The variation of 
solubility shows a linear relation with pressure at low pres-
sures, and with pressure enhancement the ScCO2 solubility 
will be increased linearly. At the pressure of the polymer 
saturation with supercritical fluid, the pressure variations 
do not have a prolonged effect on the solubility, because the 
free intermolecular volume of the polymer will be occupied 
at the saturation pressure.3 In some cases, the particle size 
declines with reduction of pressure during precipitation. In 
a situation above the critical condition, reduction in pressure 
is observed to decrease the solubility, which then results 
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Figure 3 Density dependence of CO2 at various temperatures.17
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in higher maximum supersaturation being achieved in the 
reactor; therefore, smaller particles are produced.5,28,32,45 In 
a subcritical condition, increasing the pressure produces 
smaller particles.32,37,72 Other authors found that pressure 
variations do not exert a great effect on the mean particle size 
in pressures higher than asymptotic volume expansion.8,41
Increasing the temperature reduces the solubility and 
thus enhances the maximum supersaturation, so that smaller 
particles are obtained.5,32 Also, higher temperature reduces 
the drying time and thus there is rapid removal of the residual 
solvent; therefore, more spherical particles are formed.71 
Properties of the polymers, such as viscosity, change rapidly 
with changes in the reactor conditions during spraying, and 
lead to precipitation of the polymer. If the biodegradable 
polymer is precipitated at a higher rate than it is completely 
atomized, both the size and morphology of the particles will 
be undesirable. Conversely, if the biodegradable polymer 
is not precipitated during the spraying, polymeric droplets 
are produced, and they fuse together due to their semi-fluid 
nature; thus, separate particles are not formed. Therefore, the 
best condition lies somewhere between the two scenarios.74 
The temperature needs to be lower than the glass transition 
temperature to avoid plasticizing of the polymer particles.75,76 
In amorphous polymers, CO2 molecules slip into the interstitial 
spaces of the polymers acting as lubricants and the polymers 
are plasticized.8,76 Plasticizing causes particle coalescence and 
increases the particle size.75,76 In some polymers, especially 
amorphous polymers, the glass transition temperature may 
be decreased (4–30°C/MPa) after coming in contact with the 
supercritical fluid due to CO2 activity within a very short time 
span because of the intermolecular interaction between the 
biodegradable polymer and dissolved supercritical fluid.3,8,24,30 
In a low-pressure region, the melting point of the biodegrad-
able polymer during the SAS process decreases linearly due 
to the increased pressure. The melting point is minimal at the 
saturation state of the polymer, with CO2. Later, increasing the 
pressure raises the melting point due to the hydrostatic pres-
sure effect. However, the temperature must also be sufficient 
to evaporate the solvent rapidly.3,75 Solubility increases with 
density, and the effect of density (pressure and temperature) 
is observed to be greater at higher densities. With increase in 
the density, molecular interaction is enhanced, the solubility 
is increased, and smaller particle size is obtained. Therefore, 
raising the temperature has two opposite effects on the   process; 
namely decreasing the density reduces the solubility,21,32 and 
increasing the volatility of the solvent enhances the solubility.21 
Therefore, a proper selection of sufficient temperature and 
pressure optimizes the process.
effects of concentration
The initial concentration of the solution significantly affects par-
ticle size. Different results are reported in various experiments. 
In some cases, reducing the concentration produces smaller 
particles with narrower particle size distribution. At lower 
concentrations, supersaturation of the drug occurs very late 
and, therefore, the precipitation delays and nucleation dominate 
growth, producing smaller particles. By enhancing the concen-
tration, supersaturation occurs sooner, with growth dominating 
over the nucleation process, and crystals will be formed, thus 
increasing the particle size.22,33,34,36,38,63,77 Besides, increasing 
the concentration enhances the viscosity and surface tension 
of the solution, producing larger droplets; therefore, particles 
of larger diameter will be formed.11,27,33,36,52,75,77 Conversely, in 
some cases, by increasing the concentration, the particle size 
decreases because the increased initial concentration enhances 
the maximum supersaturation and, therefore, smaller particle 
size will be formed.32,33 Actually, when the initial solution is of a 
higher concentration, the concentration of the solvent is reduced 
and then the solvent is removed more easily. In addition, more 
uniform particle size distribution is obtained as more supersatu-
ration causes homogeneous nucleation.8,33 According to the fol-
lowing explanation, the initial concentration of the solution has 
two opposite effects on particle size. On the one hand, increased 
concentration produces higher supersaturation and faster nucle-
ation; therefore particle size and its distribution will be reduced. 
On the other hand, the higher concentration will cause higher 
condensation and increase the particle size and widen particle 
size distribution. These results show that the particle size is influ-
enced by the degree of supersaturation and initial concentration, 
  simultaneously. Therefore, it becomes crucial to balance the rate 
of crystallization (nucleation) and rate of growth. As a result, 
by adjusting a lower initial concentration and higher degree of 
supersaturation of the solution, smaller particles with narrower 
particle size distribution would be obtained.18,33
effects of chemical composition  
of the organic solvent
The chemical composition of the solvent is another important 
factor that affects particle size and its distribution. Increasing the 
volatility of the solvent will decrease particle size.27,41 Solvents 
with higher volatility force the system to reach the supersatura-
tion state much faster, resulting in reduced particle size.63 The 
solubility of both the biodegradable polymer and drug in the 
organic solvent must be considered. For effective encapsulation 
of the drug, it is essential that the solubility of the biodegrad-
able polymer in the organic solvent is higher than the solubility 
of its drug content. This function results in first precipitating International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the drug, then coating it with the biodegrading polymer, and 
finally nanoencapsulation will occur.27 Also, the strength of the 
solvent is very important, too. The stronger solvents increase 
the interaction between the solvent and solute which prevents 
crystal growth, thus producing smaller particle size.63
effects of chemical composition of the 
solute (drug and biodegradable polymer)
Properties of drugs, such as partitioning in the supercritical 
fluid and solubility, are influenced by chemical composition 
and greatly affect final particle size. In the SAS process, the 
supercritical fluid acts as the antisolvent. If the drug dissolves 
in the supercritical fluid under the operating conditions, it 
will be removed into the gas phase and no precipitation will 
occur and no particles will be produced. Thus, the lower 
the solubility of the drug in the supercritical fluid, the more 
rapid will the precipitation be.59 Besides, the properties of 
the drug influence the drug loading during nanoencapsula-
tion of the drug in a biodegradable polymer.60 Some research 
has shown that enhancement of the liophilicity of the drug 
reduces the loading drug efficiency in the SAS process. This 
phenomenon explains that lipophilic drugs are entrained by 
supercritical fluid during the precipitation. The efficiency 
of the encapsulation and morphology of the particles are 
influenced by nucleation and growth mechanisms. A rapid 
initial nucleation and growth rate of the drug coupled with the 
slow rate of polymer precipitation produces the drug needles 
encapsulated in the coated biodegradable polymer.23,60
Another important factor is the structure of biodegradable 
polymer. CO2 supercritical fluid diffusivity and solubility in 
the biodegradable polymers are influenced by two variants:
 i.    Molecular structure influences the interaction between 
the supercritical fluid and molecular chains of the biode-
gradable polymer.
ii.    Morphology of polymer could be crystalline, semicrys-
talline, or amorphous and related to the free volume of 
the polymer.
For the first variant, the polymer chain flexibility must 
be considered and the availability of the reaction groups can 
enhance the dissolution of the supercritical fluid more   easily. 
For example, ether groups or carbonyl groups which are avail-
able on side chains or in the backbone can particularly inter-
act with CO2 supercritical fluid.3,15 But the most important 
factor is the morphology and free volume of the biodegrad-
able polymer.15,64 In the SAS process, the diffusivity of the 
antisolvent CO2 gas in crystalline biodegradable polymers 
is higher than in amorphous polymers. Conversely, the solu-
bility of the antisolvent CO2 gas in amorphous polymers is 
higher than in the crystalline biodegradable polymers. Both 
are because of the greater free volume in the amorphous 
polymers. Therefore, the rate of mass transfer and the result-
ing rate of precipitation are higher in the crystalline polymer, 
and there is a higher supersaturation ratio in the crystalline 
polymer than in the amorphous polymer, which results in 
smaller particles and narrower particle size distribution.15,35,67 
However, the solidification rate will be decreased by the pres-
ence of amorphous polymers; and the microparticles tend to 
aggregate due to plasticizing effects of the residual carbon 
dioxide.7,15,62,68 Particle morphology is found to be strongly 
related to the inherent characteristic of the biodegradable 
polymer molecules. The semicrystalline polymer produces 
the spherical shape, whereas the highly crystalline polymer 
probably forms fibrous or spherulitic morphology. Besides, 
the morphology of the particle produced is influenced by the 
molecular weight of the polymer that controls the dimension 
of chain polymer.24 Reducing the polymer molecular weight 
decreases the glass transition temperature and increases the 
glassy and rubbery state of the polymer.69
effects of the nozzle geometry
The diameter of the nozzle and its geometry are other fac-
tors that significantly affect particle size in the SAS   process. 
The smaller diameter of the nozzle produces a higher 
spray velocity and reduces the droplet size. However, as 
the pressure drop increases, the surface tension increases 
resulting in an enhanced mass transfer rate, and in the higher 
supersaturation, smaller particles will be formed.16,45 Also, 
the nozzle diameter influences particle morphology. Some 
research has shown that when a lower mass of solute is 
sprayed from a small-bore nozzle, it produces less cooling 
on the environment surrounding the nozzle in the reactor 
and negates the reduced temperature in the body of nozzle 
and its closed region. Therefore, the droplets sprayed 
through a smaller-bore nozzle precipitate more slowly and 
more spherical particles will be formed.74 Other research 
has shown that the effect of the nozzle diameter is not very 
significant. Its effect was explained according to the Weber 
number, which is the proportion of the internal and surface 
forces and related to the fluid velocities and surface tension. 
During the SAS process, under supercritical conditions, 
the surface tension is approximately equal to zero and 
the Weber number is no longer applicable. Therefore, the 
variation in solution velocity does not significantly affect 
the break-up behavior.26
Reverchon et al explained that the smaller droplets were 
obtained with faster jet break-up than surface tension. He International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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proposed two different mechanisms for particle production 
according to these characteristic times: namely, time of the sur-
face tension vanishing, which is the required time to decrease 
the surface tension near to zero (τstv), and time of the jet break 
up, which is the required time to break the liquid jet at the exit 
of the nozzle [(τ)jb]. If τstv , τjb, then the gas plume process will 
occur. In contrast, if τstv . τjb, jet break-up will occur to produce 
the droplets. These two mechanisms are shown in Figure 4.22 
With formation of the droplets, the supercritical antisolvent 
diffuses toward the liquid interface. Because the surface ten-
sion tends to vanish after the droplets’ production and during 
their drying, the original spherical shape of particles is main-
tained.22 The process can be improved by spraying the drug 
and biodegradable polymers through two different co-axial 
nozzles to generate smaller particle size.15,18,34 The co-axial 
nozzle is specially designed to improve the particle morphol-
ogy. The solution is sprayed through the core of the nozzle and 
the supercritical fluid through the annulus. The schematic of 
the co-axial nozzle is shown in Figure 5. By decreasing the 
Weber number, atomization is reduced and larger droplets are 
produced in the jet. For high-viscosity supercritical fluids and 
therefore higher Reynolds number, the mass transfer outside 
of the jet is faster, which results in less agglomeration.58
Effects of flow rates of CO2 and liquid 
phase
Increasing the ratio of CO2 flow rate to the organic solution flow 
rate reduces the particle size. Enhancing the solution flow rate 
increases the system turbulence, thus improving the mixing of 
agents. Therefore, higher supersaturation occurs in the system, 
forming smaller particle sizes. Hence, the composition of the 
bulk fluid is reduced by CO2 flow rate which affects CO2 dis-
solving in the organic solvent solution. If the CO2 flow rate 
decreases, the amount of bulk fluid declines to less than the 
amount of organic solvent. Therefore, the solubility of the solute 
will be reduced and smaller particles will be produced.72,77
Larger particles with broader particle size distribution 
could be obtained by reduction in the CO2 molar fraction. By 
decreasing the CO2 molar fraction, the fluid phase produced 
in the reactor contained larger quantities of the solvent and 
therefore solubilization and solute precipitation processes 
occur more slowly. Thus, the microparticles production 
process shifts toward the growth process and therefore larger 
particles would be produced.11,52
For production of the spherical microparticles, mole 
fraction of CO2 must be larger than the mole fraction at 
which the binary mixture CO2–liquid solvent shows the 
mixture critical point (MCP). Mixture critical point depends 
on the temperature and the nature of the liquid phase. The 
best conditions for production of spherical microparticles 
are at the pressure above the critical pressure of the 
mixture; the CO2 mole fraction above the MCP is shown 
as the shaded region in Figure 6.22 The observations are 
summarized in Table 2.
Nozzle exit
Gas plume
Liquid droplets drying
Spherical microparticles
Nucleation and growth of
nanoparticles from
gaseous phase
Jet break-up
(atomization)
τstv < τjb τstv > τjb
Figure 4 The two mechanisms in competition for particles formation during the 
supercritical antisolvent process at P . PC and XCO2 $ XMCP.22
Note:  Reprinted  from  The  Journal  of  Supercritical  Fluids,  vol  47,  Reverchon  e, 
Adami R, Caputo G, De Marco I, Spherical microparticles production by supercritical 
antisolvent precipitation: interpretation of results, pages 70–84, copyright 2008, 
with permission from elsevier.
S.F. S.F.
Solution of
pharmaceutical
substance
Figure 5 Coaxial nozzle employed for the simultaneous introduction of the organic 
solution and the supercritical antisolvent process.34
Note: Reprinted with permission from Kalogiannis CG, Pavlidou e, Panayiotou CG. 
Production of amoxicillin microparticles by supercritical antisolvent precipitation. Ind 
Eng Chem Res. 2005;44:9339–9346. Copyright 2005 American Chemical Society.
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Drug release mechanisms
The encapsulation of pharmaceutical ingredients using a 
suitable polymer is an interesting method for controlled 
drug delivery. The drug release from the polymer occurs in 
a sustained manner and the dose of drug is controlled at the 
optimal therapeutic effects. The polymer can also protect 
fragile drugs such as peptides and proteins. It can reduce drug 
administration frequency and improve patient compliance. 
In controlled drug delivery, polymer-based microspheres 
can have two different structures, namely a matrix structure 
or an encapsulated structure. In a matrix structure, a solid 
phase disperses inside another solid phase, while in an encap-
sulated structure or reservoir structure a core of material is 
coated by another solid phase. These structures are shown 
in Figure 7.
The drug can be released from a polymer by either 
diffusion mechanism or degradation mechanisms. During 
Table 2 effects of the process parameters on the particle size in the supercritical antisolvent (SAS) process
Effects Ref
Effects of pressure
At higher pressure, obtained smaller particle size. At higher pressure, the deforming pressure forces must be increased  
to break the droplets into smaller particles. Moreover, particle nucleation and its growth are other important factors affecting  
particle size. Rapid mass transfer of antisolvent and solvent causes high supersaturations for the solute. High supersaturation  
results in rapid nucleation and growth of more than one particle per primary droplet.
56,63,72–73
At lower pressure, obtained smaller particle size. In a situation above the critical condition, reduction in pressure is observed to  
decrease the solubility which then results in higher maximum supersaturation in the reactor; therefore, smaller particles are produced.
32,42,45
Pressure variations have no significant effect on particle size because the free intermolecular volume of the polymer will be  
occupied at the saturation pressure.
8,41,63
Effects of temperature
At higher temperature, smaller size and more spherical particles obtained. But the temperature must be lower than  
the Tg of the polymer.
32,42,63,72,78
At lower temperature, smaller particle size, obtained due to higher volatility. 32,73
Effects of concentration
At higher concentration, smaller particle size obtained because the increased initial concentration enhances the maximum 
supersaturation and, therefore, smaller particles will be formed.
8,32–33
At lower concentration, smaller particle size obtained because supersaturation of the drug occurs very late and therefore,  
the precipitation delay and nucleation dominate growth, producing smaller particles.
27,33,36,42,63, 
72,73,75
Effects of chemical composition of the organic solvent
Particle size decreases with increase in volatility of the solvent. 27,41
Particle size decreased by using a stronger solvent. 41
Solubility of the biodegradable polymer in the organic solvent must be higher than the solubility of its drug contents. 27
Effects of chemical composition of the drug
Lower solubility of the drug in a supercritical fluid enhances rapid precipitation. 29,60
Enhancement of drug lipophilicity reduces the loading drug efficiency in the SAS process. 29,59
Effects of chemical composition of the biodegradable polymer
The crystalline polymer forms smaller particle size with narrower particle size distribution. 7,67–68
Drug stability in amorphous polymers is higher than in crystalline polymers. 67–68
Effects of the nozzle geometry
A smaller nozzle diameter reduces the particle size and produces more spherical-shaped particles. 45,63
The effect of the nozzle diameter is not highly significant. 63
Co-axial nozzle, is especially designed for improvement of the morphology. 45,63
Effects of flow rates of CO2 and liquid phase
Increasing the ratio of CO2 flow rate over the organic solution flow rate reduces particle size. 72,77
Abbreviation: Tg, glass transition temperature.
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Figure 6 Qualitative diagram pressure versus CO2 molar reaction.22
Note: Reprinted from The Journal of Supercritical Fluids, vol 47, Reverchon e, Adami 
R,  Caputo  G,  De  Marco  I,  Spherical  microparticles  production  by  supercritical 
antisolvent precipitation: interpretation of results, pages 70–84, copyright 2008, 
with permission from elsevier.
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diffusion, the drug can pass through the polymer pores or 
chains. In this release mechanism, smart polymers have to 
be chosen which a permeability related to the environmental 
conditions. During the degradation mechanism, the biodegrad-
able polymer degrades in the body due to the natural biological 
reactions. The degradation depends on the chemical structure 
and molecular weight of polymer. Therefore, the selection of a 
suitable polymer is critical for controlled drug delivery.79–81
Conclusion
Recently, processing of pharmaceutical compounds with 
supercritical fluid has received increased attention. Conven-
tional methods cannot usually encapsulate drugs with a rate-
controlled release or that target a specific site. Conventional 
drugs provide almost a sharp drug release and thus provide 
potentially toxic levels. New methods using biodegradable 
polymers can control the drug release rate. Encapsulation 
by means of supercritical fluid is of great interest in the 
pharmaceutical industries because of its ability to produce 
uniform particle size and controlled morphology. Due to the 
nonuniform temperature in conventional encapsulation meth-
ods, nonuniform supersaturation occurs, and thus nonuniform 
crystallization takes place and results in a broad particle 
size distribution. Conversely, in SAS fluid encapsulation, 
the mass transfer is so fast that it produces fine particles 
with a narrower size distribution. In the SAS process, the 
solvent and supercritical CO2 interaction plays the key role, 
while temperature and CO2 dissolution parameters control 
the process. Encapsulation of pharmaceutical products in 
biodegradable polymers is useful to control the rate of drug 
release within the body. Supercritical CO2 fluid is a relatively 
poor solvent for most biodegradable polymers and pharma-
ceutical products. Therefore, the SAS process is a suitable 
technique to produce fine spherical particles. Because the 
process conditions influence particle size and morphology, 
it is crucial to optimize the process parameters to produce 
smaller particle size with narrower size distribution.
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